Edison Pharmaceuticals Nabs $20M To Treat Mitochondrial Disease

Mountain View-based Edison Pharmaceuticals, a biopharmaceuticals firm developing treatments for mitochondrial diseases, has raised $20M in a Series F funding. The round was led by Mitsui & Co. Edison said the funding will go to advance clinical development of its EPI-743 compound. Mitsui gains a seat on the board with the funding. More information »